A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors

Cancer Letters

Volumn 235, Issue 1, 2006, Pages 147-153

  Triebel, Frédéric ^a   Hacene, Kamel ^b   Pichon, Marie France ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast carcinoma; MHC class II; Oestrogen receptors; Progesterone receptors; Prognosis

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGESTERONE RECEPTOR; PROTEIN DERIVATIVE; SOLUBLE LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; HUMAN; HYPOTHESIS; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; TH1 CELL; TREATMENT RESPONSE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33645842230     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.04.015     Document Type: Article

References (27)

1. Hadden J.W. The immunology and immunotherapy of breast cancer: an update. Int. J. Immunopharmacol. 21 (1999) 79-101
2. Georgiannos S.N., Renaut A., Goode A.W., and Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 134 (2003) 827-834
3. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190 (1999) 1417-1426
4. Neidhardt-Berard E.M., Berard F., Banchereau J., and Palucka A.K. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 6 (2004) R322-R328
5. Triebel F., Jitsukawa S., Baixeras E., Roman-Roman S., Genevée C., Viegas-Pequignot E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171 (1990) 1393-1405
6. Baixeras E., Huard B., Miossec C., Jitsukawa S., Martin M., Hercend T., et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176 (1992) 327-337
7. Huard B., Gaulard P., Faure F., Hercend T., and Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, a MHC class II ligand. Immunogenetics 39 (1994) 213-217
8. Huard B., Prigent P., Tournier M., Bruniquel D., and Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 25 (1995) 2718-2721
9. El mir S., and Triebel F. A soluble LAG-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J. Immunol. 164 (2000) 5583-5589
10. Andreae S., Piras F., Burdin N., and Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J. Immunol. 168 (2002) 3874-3880
11. Buisson S., and Triebel F. MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine receptor expression by human dendritic cells. Vaccine 21 (2003) 862-868
12. Prigent P., Mir S.E., Dreano M., and Triebel F. LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur. J. Immunol. 29 (1999) 3867-3876
13. Cappello P., Triebel F., Iezzi M., Caorsi C., Quaglino E., Lollini P.L., et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63 (2003) 2518-2525
14. Avice M.N., Sarfati M., Triebel F., Delespesse G., and Demeure C.E. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J. Immunol. 162 (1999) 2748-2753
15. Andreae S., Buisson S., and Triebel F. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102 (2003) 2130-2137
16. Di Carlo E., Cappello P., Sorrentino C., D'Antuono T., Pellicciotta A., Giovarelli M., et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J. Pathol. 205 (2005) 82-91
17. +T cell clone response following LAG-3 binding. Eur. J. Immunol. 26 (1996) 1180-1186
18. Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol. 24 (2003) 619-622
19. Annunziato F., Manetti R., Tomasevic L., Guidizi M.-G., Biagiotti R., Gianno V., et al. Expression and release of LAG-3-encoded protein by human CD4+T cells are associated with IFN-gamma production. Fed. Am. Soc. Exp. Biol. J. 10 (1996) 769-776
20. Lienhardt C., Azzurri A., Amedei A., Fielding K., Sillah J., Sow O.Y., et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol. 32 (2002) 1605-1613
21. Bloom H.J., and Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 11 (1957) 359-377
22. Amedei A., Romagnani C., Benagiano M., Azzurri A., Fomia F., Torrente F., et al. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur. J. Immunol. 31 (2001) 1927-1934
23. Kaplan E., and Meier P. Non parametric estimation for incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
25. Cox D. Regression models and life tables. J. R. Stat. Soc. 34 (1972) 187-200
26. Annunziato F., Manetti R., Cosmi L., Galli G., Heusser C.H., Romagnani S., et al. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur. J. Immunol. 27 (1997) 2239-2244
27. Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., et al. Role of LAG-3 in regulatory T cells. Immunity 21 (2004) 503-513